Tango Therapeutics, Inc. Operating Lease, Liability, Noncurrent
Tango Therapeutics, Inc. (TNGX) had Operating Lease, Liability, Noncurrent of $29.05 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability, Noncurrent $29.05M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $29.96M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $30.83M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $31.66M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $29.05M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $29.96M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $30.83M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $31.66M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $32.47M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $34.12M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $34.04M 10-K · filed 2026-03-05 |
| 2024-09-30 | $34.76M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $35.47M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $36.17M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $36.84M 10-K · filed 2025-02-27 |
| 2023-09-30 | $37.47M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $38.08M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $38.73M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $39.36M 10-K · filed 2024-03-18 |
| 2022-09-30 | $39.95M 10-Q · filed 2022-11-10 |
| 2021-09-30 | $6.09M 10-Q · filed 2021-11-09 |
| 2020-12-31 | $6.92M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |